Test Trial for Go-Live for data migration - testExclusion Criteria:The presence of any active, known, or suspected autoimmune disease. Type 1 diabetes, which was admitted to receive stable dose of insulin, hypothyroidism, which required only hormone replacement therapy, skin disease with no need to systemic treatment and no acute exacerbation within 1 year before the screening period;Subjects who had received systemic treatment with corticosteroids or other immunosuppressive agents within 28 days prior to initial administration.Known and untreated central nervous system (CNS) or leptomeningeal metastases;Uncontrolled pleural effusion,or ascites requiring recurrent drainage procedures;Uncontrolled cardiac diseases or symptoms;Known hereditary or acquired bleeding and thrombotic tendencies;Patients who have previously received chemotherapy, radiotherapy or surgery which ended within 4 weeks prior to the start of this study; oral molecular targeted therapy with Known active infection,;Congenital and acquired immune deficiency;HBsAg-positive and HBV DNA > 2000 IU/mL(or 104 copies/mL); HCV RNA copies > ULN;Patients with other potential factors that may affect the study results or result in the premature discontinuation as determined by the investigator, such as alcoholism, drug abuse, other serious diseases (including mental illness) requiring concomitant treatment, serious laboratory abnormalities, or family or social factors that could affect the safety of the patients. 

The Precision Psychopathology +Dynamic Immunopsychiatry (PPDI) Lab is looking for people who are currently experiencing depression to participate in a clinical trial designed to measure the effect of an anti-inflammatory medication (Simlandi/adalimumab-ryvk) on persisting depression symptoms in people already taking an anti-depressant.  

Dr. Anuja Dokras and the PCOS Center at the University of Pennsylvania are running a research study for individuals with polycystic ovarian syndrome (PCOS) who are between the ages of 18 -and 40 and have a BMI of 25 to 48.The research study is being conducted to see if a dietary fiber supplement when combined with oral contraceptive pills (OCPs) can improve risk factors for heart health and the underlying cardiovascular disease such as cholesterol levels in overweight or obese women with Polycystic Ovary Syndrome (PCOS). The study will take place for 12 weeks and compare a group of PCOS patients that get the fiber supplement to a group who get a placebo (a harmless powder that contains no dietary fiber).If you agree to join the study the research team will collect information about your medical and gynecological history, have exams and transvaginal ultrasound, and have you fill out questionnaires, collect fasting blood samples, complete food diaries, and complete an oral glucose tolerance test. You will be prescribed OCPs and be randomized to either a dietary fiber supplement or to a placebo for 12 weeks.